Wockhardt files fast-acting Insulin Aspart injection with DCGI

Wockhardt, a global pharmaceutical and biotechnology major, announces the filing of its fast-acting insulin analog, Aspart injection (ASPARAPIDTM), with the Drugs Controller General of India (DCGI). This significant milestone reflects Wockhardt's ongoing commitment to address the growing diabetes epidemic both in India and globally.

Diabetes remains a critical health issue, affecting more than 77 million people in India and over 537 million people worldwide and expected to be over 643 million by 2030. The prevalence of diabetes is rising sharply, driven by lifestyle changes, aging population, and urbanization.

Wockhardt's Aspart insulin injection (ASPARAPIDTM) is an indigenously developed product, underscoring the company's end-to-end capabilities in research & development, clinical studies, scale up and manufacturing of biosimilars products. By leveraging integrated infrastructure and expertise, Wockhardt has completed all stages of ASPARAPIDTM development - from research to production through in-house development. It offers enhanced quality and accessibility for patients. ASPARAPIDTM will be available in cartridges, vials, and prefilled disposable pens, offering flexibility to the patients for management of diabetes. The market size of Aspart in India is currently estimated over INR 260 Cr. with only 2 players and is expected to grow significantly in the coming years.

"We are proud of adding another feather in our diabetes biosimilars portfolio through filing of insulin Aspart injection in a market that has limited competition. This reinforces Wockhardt's ability to develop and manufacture complex biosimilars domestically," said Dr. Habil Khorakiwala, Founder Chairman of Wockhardt. "Our aim is to make world-class diabetes care accessible to patients in India and globally and to contribute meaningfully to the management of diabetes."

Wockhardt is also developing additional insulin analogs and GLP-1 agonists as part of its comprehensive strategy to provide advanced diabetes care solutions. The introduction of these products will further strengthen Wockhardt's diabetes portfolio, offering patients more effective treatment options for managing their condition.

Shares of Wockhardt Limited was last trading in BSE at Rs. 1080.55 as compared to the previous close of Rs. 1044.65. The total number of shares traded during the day was 160405 in over 3126 trades.

The stock hit an intraday high of Rs. 1096.85 and intraday low of 1057.00. The net turnover during the day was Rs. 175214250.00.

Source : Equity Bulls

Keywords

Wockhardt INE049B01025 FastActingInsulinAnalog AspartInjection ASPARAPID DCGI